WELCOME TO CHARLES RUSSELL SPEECHLYS.
We would like to place strictly necessary cookies and performance cookies on your computer to improve our website service.
Otherwise, we'll assume you are OK to continue. Please close this message
The CMA has issued a statement of objections to the pharmaceutical suppliers Pfizer and Flynn Pharma alleging that they have abused a dominant position by charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug. Click here.
The CMA has issued its final report in relation to Reckitt Benckiser’s anticipated acquisition of the K-Y brand, concluding that the merger could lead to a substantial lessening in competition. This confirms the CMA’s provisional findings which were published in May. To remedy these concerns, RB will be required to license the K-Y brand in the UK to a competitor for 8 years. Click here.
The CMA has provisionally cleared the proposed merger between the Ashford and St Peter’s Hospitals NHS Foundation Trust and the Royal Surrey County Hospital NHS Foundation Trust, following a phase 2 merger investigation. Click here.